Onconetix, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Onconetix, Inc. (ONCO) reported Revenue from Contract with Customer, Excluding Assessed Tax of $406.86 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-12-10.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2024-12-10
- Onconetix, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $406.86K.
- Onconetix, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $704.85K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month |
|---|---|---|---|
| 2024-09-30 | $406.86K 10-Q · filed 2024-12-10 | $1.11M derived: sum of 2 quarters · filed 2024-12-10 | $1.81M 10-Q · filed 2024-12-10 |
| 2024-06-30 | $704.85K 10-Q · filed 2024-08-29 | $1.41M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |